<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="343280">
  <stage>Registered</stage>
  <submitdate>31/07/2011</submitdate>
  <approvaldate>16/08/2011</approvaldate>
  <actrnumber>ACTRN12611000869976</actrnumber>
  <trial_identification>
    <studytitle>A substudy of the PLAPCI trial comparing Phospholipase A2 release with tissue characteristics as determined by invasive ultrasound and infrared imaging of the heart arteries in patients with coronary artery disease undergoing coronary artery stenting.</studytitle>
    <scientifictitle>The release of Phospholipase A2 biomarkers during percutaneous coronary intervention in patients with significant coronary artery disease and the relationship of released biomarkers with optical coherence tomography and intravascular ultrasound tissue characterisation.</scientifictitle>
    <utrn>U1111-1121-2268</utrn>
    <trialacronym>PLAPCI imaging substudy</trialacronym>
    <secondaryid>SCGH 2011-082</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Coronary artery disease</healthcondition>
    <conditioncode>
      <conditioncode1>Cardiovascular</conditioncode1>
      <conditioncode2>Coronary heart disease</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Invasive imaging of the coronary arteries prior to and after elective coronary stenting with optical coherence tomography and intravascular ultrasound. Imaging will take place on two occasions approximately 30 minutes apart and will take 15-20minutes to perform on each occasion.</interventions>
    <comparator>nil</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Diagnosis / Prognosis</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>To test the hypothesis that a greater percentage of coronary lipid core and the presence of thin cap fibro-atheroma as assessed by IVUS and OCT will correlate with greater relative PLA2 release during elective percutaneous coronary intervention and to identify which PLA2 assay shows the greatest correlation</outcome>
      <timepoint>prior to and after elective coronary intervention (approx 30mins apart)</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>nil</outcome>
      <timepoint>nil</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Patients undergoing elective percutaneous coronary intervention
age 18 to 85 years</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>85</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Myocardial Ischaemic event &lt;14 days prior to participation
Change in HMG Co-A reductase inhibitor (statin) in the last 30 days
Current acute or chronic inflammatory condition
Coronary vessels unsuitable for invasive imaging, including planned left main stenting</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Diagnosis</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment>All patients enrolled will be assessed with invasive imaging (optical coherence tomography and intravascular ultrasound)</concealment>
    <sequence>nil</sequence>
    <masking>Open (masking not used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>1/10/2011</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>50</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>Sir Charles Gairdner Hospital</primarysponsorname>
    <primarysponsoraddress>Hospital Ave
Nedlands 6009
WA</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Self funded/Unfunded</fundingtype>
      <fundingname />
      <fundingaddress />
      <fundingcountry />
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The aim of this study is to assess the effect of elective coronary stenting procedures on the release of enzymes (PLA2) found in the wall of the coronary artery, and how this release relates to the characteristics of the artery wall as assessed by novel invasive imaging tools</summary>
    <trialwebsite>nil</trialwebsite>
    <publication />
    <ethicsreview>Not yet submitted</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname />
      <ethicaddress />
      <ethicapprovaldate />
      <hrec>2011-082</hrec>
      <ethicsubmitdate>10/08/2011</ethicsubmitdate>
      <ethiccountry />
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Dr Chris Judkins</name>
      <address>Cardiovascular Medicine
4th Floor, G Block
Sir Charles Gairdner Hospital
Hospital Avenue
Nedlands 6009
WA</address>
      <phone>+61 (0) 414468332</phone>
      <fax />
      <email>chrisjudkins@hotmail.com</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr Chris Judkins</name>
      <address>Cardiovascular Medicine
4th Floor, G Block
Sir Charles Gairdner Hospital
Hospital Avenue
Nedlands 6009
WA</address>
      <phone>+61 (0) 414468332</phone>
      <fax />
      <email>chrisjudkins@hotmail.com</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr Chris Judkins</name>
      <address>Cardiovascular Medicine
4th Floor, G Block
Sir Charles Gairdner Hospital
Hospital Avenue
Nedlands 6009
WA</address>
      <phone>+61 (0) 414468332</phone>
      <fax />
      <email>chrisjudkins@hotmail.com</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>